RE:5 quartersWhy would it be delayed beyond April?
LAVAL, QC, Oct. 13, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its plasminogen replacement therapy (RyplazimTM) having granted a priority review status and set a Prescription Drug User Fee Act (PDUFA) action date for April 14, 2018, Ryplazim™ had previously been granted Fast Track, Orphan Drug and Rare Pediatric Disease designations by the U.S. FDA.
PDUFA is a deadline date by which the FDA MUST respond to a BLA. Unless "the BIG GUYS" know that it won't be approved (highly unlikely they have inside knowledge of the BLA) there's no basis to your statement!!!
On a side note check out this link and scroll through to April 2018
https://www.fdatracker.com/fda-calendar/'
Garth